Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 5Terminated 2

Sponsor Class

OTHER 4INDUSTRY 2INDIV 1

Study Type

Interventional 2

Sponsor

Conditions

Leiomyoma 1Cushing Syndrome 1ACTH Syndrome, Ectopic 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Mifepristone × Clear all
NCT00422201 2019-10-11

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

HRA Pharma

Phase 2 Terminated
18 enrolled 9 charts

ACTH Syndrome, Ectopic, Cushing Syndrome

NCT03210324 2019-08-07

A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy

China Resources Zizhu Pharmaceutical Co., Ltd.

Phase 4 Terminated
434 enrolled

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡